

Date: Friday, 30th July 2021
Our Ref: MB/SS FOI 4815

Sid Watkins Building
Lower Lane
Fazakerley
Liverpool L9 7BB
Tel: 01515253611
Fax: 01515295500
Direct Line: 01515563038

Re: Freedom of Information Request FOI 4815

We are writing in response to your request submitted under the Freedom of Information Act, received in this office on 19th July 2021.

Your request was as follows:

Q1. How many patients have been treated in the last 6 months (for any disease) with the following products:

- Aranesp & Aranesp SureClick (darbepoetin alpha)
- Eprex (epoetin alfa)
- NeoRecormon (epoetin beta)
- Retacrit (epoetin zeta)
- Mircera (methoxy polyethylene glycol-epoetin beta)
- Ferinject (ferric carboxymaltose injection/infusion)
- Diafer (ferric derisomaltose injection)
- Monofer (ferric derisomaltose injection)
- Cosmofer (iron dextran injection)
- Venofer (iron sucrose injection)

DARBEPOETIN ALFA 150 micrograms in 0.3ml syringe 1
DARBEPOETIN ALFA 40 micrograms in 0.4ml syringe 1
DARBEPOETIN ALFA 50 micrograms in 0.5ml syringe 2
DARBEPOETIN ALFA 60 micrograms in 0.3ml syringe 1
FERRIC CARBOXYMALTOSE (FERINJECT) 1000 mg in 20mL injection 4
FERRIC DERISOMALTOSE (MONOFER) 1000 mg in 10ml injection 1
IRON DEXTRAN (COSMOFER) 100 mg in 2ml injection 2
IRON DEXTRAN (COSMOFER) 500 mg in 10ml injection 3

Any drugs not mentioned means that we have had no patients treated with the drugs in the last 6 months

Q2. In the past 6 months could you please state the number of patients treated for the following conditions:

- Chronic kidney disease (ICD10 code - N.18)
- Chronic kidney disease - Stages 4 & 5 (ICD10 codes - N.18.3 & N.18.4 & N.18.5)

- Acquired cystic kidney disease (ICD10 code N28.1)
- Chronic kidney disease - new patients (excluding previously treated patients)
- Acquired cystic kidney disease - new patients (excluding previously treated patients)

The Walton Centre NHS Foundation Trust is a Specialist Neuroscience Tertiary Care Centre; we would not receive referrals to treat patients for the condition you have mentioned above, therefore we cannot provide this information.

Q3. Please indicate the number of patients treated in the last 6 months for chronic kidney disease ONLY with each of the following products:

- Aranesp & Aranesp SureClick (darbepoetin alpha)
- Eprex (epoetin alfa)
- NeoRecormon (epoetin beta)
- Retacrit (epoetin zeta)
- Mircera (methoxy polyethylene glycol-epoetin beta)
- Ferinject (ferric carboxymaltose injection/infusion)
- Diafer (ferric derisomaltose injection)
- Monofer (ferric derisomaltose injection)
- Cosmofer (iron dextran injection)
- Venofer (iron sucrose injection)

The Walton Centre NHS Foundation Trust is a Specialist Neuroscience Tertiary Care Centre; we would not receive referrals to treat patients for the condition you have mentioned above, therefore we cannot provide this information.

Please see our response above in [blue](#).

Re-Use of Public Sector Information

All information supplied by the Trust in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2005, Statutory Instrument 2005 No. 1515 which came into effect on 1st July 2005.

Under the terms of the Regulations, the Trust will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however the Trust reserves the right, in certain circumstances, to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information can be found at www.opsi.gov.uk where a sample license terms and fees can be found with guidance on copyright and publishing notes and a Guide to Best Practice and regulated advice and case studies, at www.opsi.gov.uk/advice/psi-regulations/index.htm

If you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to the Freedom of Information Office at the address above.

Please remember to quote the reference number, FOI 4815 in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioners Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF.

Yours sincerely

Mike Burns

Mr. Mike Burns, Executive Lead for Freedom of Information